Articles published by NervGen Pharma Corp.

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

February 11, 2026

From NervGen Pharma Corp.

Via GlobeNewswire

Tickers NGEN NGENF TSX-V:NGEN

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

February 09, 2026

From NervGen Pharma Corp.

Via GlobeNewswire

Tickers NGEN NGENF TSX-V:NGEN

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

January 20, 2026

From NervGen Pharma Corp.

Via GlobeNewswire

Tickers NGEN NGENF TSX-V:NGEN

NervGen Pharma Begins Trading on Nasdaq Today

January 08, 2026

From NervGen Pharma Corp.

Via GlobeNewswire

Tickers NGEN NGENF TSX-V:NGEN

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

June 02, 2025

From NervGen Pharma Corp.

Via GlobeNewswire

Tickers NGENF TSX-V:NGEN

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University

July 28, 2022

From NervGen Pharma Corp.

Via Business Wire

Tickers NGENF TSX-V:NGEN

NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation

January 10, 2022

From NervGen Pharma Corp.

Via Business Wire

Tickers NGENF

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.